Previous 10 | Next 10 |
Concert Pharma ( NASDAQ: CNCE ) stock fell sharply on Monday despite the biopharma reporting a loss lighter than expected for third quarter. The Lexington-based drug developer focused on the treatment of autoimmune diseases reported a loss of $0.58 per share, notching ...
Concert Pharmaceuticals, Inc. (CNCE) Q3 2022 Earnings Conference Call November 07, 2022, 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Corporate Communications and Investor Relation Roger Tung - President and Chief Executive Officer ...
Concert Pharma press release ( NASDAQ: CNCE ): Q3 GAAP EPS of -$0.58 beats by $0.01 . Revenue of $0.08M (-84.0% Y/Y) in-line. Cash, cash equivalents and investments as of September 30, 2022 totaled $148.9 million, compared to $141.6 million as of December 31, 2021....
Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to...
Concert Pharma ( NASDAQ: CNCE ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is -$0.59 and the consensus Revenue Estimate is $0.08M (-84.0% Y/Y). Over the last 3 months, EPS estimates have seen 4 ...
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss i...
35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Patients Treated With Both...
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022. The on-demand webcast of the p...
September is Alopecia Areata Awareness Month Alopecia Areata is a Serious Autoimmune Disorder with Limited Treatment Options In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated...
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31 st European Academy ...
News, Short Squeeze, Breakout and More Instantly...
Concert Pharmaceuticals Inc. Company Name:
CNCE Stock Symbol:
NASDAQ Market:
Concert Pharmaceuticals Inc. Website:
Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibit...
NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Concert Pharmaceuticals, Inc. (NASDAQ...
If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Mark...